Mepolizumab Reduces Flares in Patients With Hypereosinophilic Syndrome
Brian Park, PharmD Results showed 50% fewer patients in the mepolizumab treatment arm experienced an HES flare GlaxoSmithKline announced positive results from the pivotal phase 3 study of mepolizumab in the…